Alicaforsen for the treatment of inflammatory bowel disease

References

• Marafini I, Di Fusco D, Calabrese E, et al. Antisense approach to inflammatory bowel disease: prospects and challenges. Drugs. 2015;75:723–730.
   PubMed Web of Science ®Google Scholar
• Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol. 1986;137:245–254.
   PubMed Web of Science ®Google Scholar
• Vainer B, Nielsen OH. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol. 2000;121:242–247.
   PubMed Web of Science ®Google Scholar
• Vainer B, Sorensen S, Nielsen OH, et al. Subcellular localization of intercellular adhesion molecule-1 in colonic mucosa in ulcerative colitis. Ultrastruct Pathol. 2002;26:113–121.
   PubMed Web of Science ®Google Scholar
• Philpott JR, Miner PB Jr. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD. Expert Opin Biol Ther. 2008;8:1627–1632.
   PubMed Web of Science ®Google Scholar
• Morcos PA. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos. Biochem Biophys Res Commun. 2007;358:521–527.
   PubMed Web of Science ®Google Scholar
• Hosten TA, Zhao K, Han HQ, et al. Alicaforsen: an emerging therapeutic agent for ulcerative colitis and refractory pouchitis. Gastroenterology Res. 2014;7:51–55.
   PubMedGoogle Scholar
• Miner P, Wedel M, Bane B, et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19:281–286.
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn’s disease. Aliment Pharmacol Ther. 2002;16:1761–1770.
   PubMed Web of Science ®Google Scholar
• Miner PB Jr., Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1427–1434.
   PubMed Web of Science ®Google Scholar
• Hamamoto N, Maemura K, Hirata I, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol. 1999;117:462–468.
   PubMed Web of Science ®Google Scholar
• Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121:1428–1436.
   PubMed Web of Science ®Google Scholar
• Crooke ST. Progress in antisense technology. Annu Rev Med. 2004;55:61-95.:61-95.
   PubMed Web of Science ®Google Scholar
• Glover JM, Leeds JM, Mant TG, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther. 1997;282:1173–1180.
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey W, Goff J, et al. A randomized, placebo-controlled trial of antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn’s disease showed clinical improvement at high serum levels. Gastroenterology. 2001;120:A279–A280.
   Web of Science ®Google Scholar
• Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut. 2002;51:30–36.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease. Gastroenterology. 2001;120:1339–1346.
   PubMed Web of Science ®Google Scholar
• Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin Gastroenterol Hepatol. 2007;5:215–220.
   PubMed Web of Science ®Google Scholar
• Lobaton T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579–594.
   PubMed Web of Science ®Google Scholar
• Tiainen J, Matikainen M. Health-related quality of life after ileal J-pouch-anal anastomosis for ulcerative colitis: long-term results. Scand J Gastroenterol. 1999;34:601–605.
   PubMed Web of Science ®Google Scholar
• Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02525523?term=alicaforsen&rank=1
   Google Scholar
• Van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646–1651.
   PubMed Web of Science ®Google Scholar
• Van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1415–1425.
   PubMed Web of Science ®Google Scholar
• Miner PB Jr., Wedel MK, Xia S, et al. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalamine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23:1403–1413.
   PubMed Web of Science ®Google Scholar
• Vegter S, Tolley K, Wilson Waterworth T, et al. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2013;38:284–293.
   PubMed Web of Science ®Google Scholar
• Henry SP, Novotny W, Leeds J, et al. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 1997;7:503–510.
   PubMedGoogle Scholar